YANTRA declared theme for India's National Technology Day 2025
New Delhi: The Technology Development Board (TDB), under the Department of Science and Technology (DST), on Saturday announced the official theme for National Technology Day 2025.
This year's theme is 'YANTRA – Yugantar for Advancing New Technology, Research and Acceleration'.
The word 'YANTRA' has deep roots in India's scientific traditions and cultural history.
It stands for more than just machines; it symbolises the power of systems, teamwork, and scalable solutions.
The term 'Yugantar', which means a major shift or turning point in time, reflects India's progress from simply adopting technology to becoming a global technology leader.
National Technology Day is celebrated every year on May 11 to mark India's major technological achievements.
On this day in 1998, India successfully carried out nuclear tests under Operation Shakti.
It was also the day when the indigenously developed aircraft Hansa-3 made its first flight.
In honour of these milestones, then Prime Minister Atal Bihari Vajpayee declared May 11 as National Technology Day.
Over the years, this day has become a symbol of India's growing strength in science and technology.
It is a time to recognise outstanding scientific work, highlight innovation in industry, and build stronger connections between science, society, and business.
The 2025 celebration will be hosted by TDB-DST. The event will bring together policymakers, scientists, industry experts, academic institutions, and startup leaders.
They will discuss how to speed up India's growth in areas like deep-tech, precision engineering, and advanced research and development.
Gaurav Shukla, Partner at Deloitte India, shared his thoughts on the occasion. He said that infrastructure and digital transformation are key to building a developed India or 'Viksit Bharat'.
He highlighted the role of young people, calling them India's largest group of digital citizens and future tech leaders.
'Cyber resilience should become second nature for the youth to protect against rising digital threats,' Shukla stated.
'India has the potential to become a global leader in artificial intelligence-powered cyber defence. A secure digital India — #CyberSurakshitBharat — that is strong by design and united in purpose, is the future the country must aim for,' he mentioned. (IANS)
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
8 hours ago
- Yahoo
Ukrainian company Skyeton to manufacture Raybird drones in EU
Skyeton, a Ukrainian manufacturer of unmanned aerial systems, has demonstrated the production of Raybird drones in the European Union. Source: Defender media Details: The company's press release states that the drones are already being delivered to customers in partner countries. Production is organised at a plant in Slovakia owned by the Tropozond company, which is part of the Skyeton Group. The company conducted a short video tour of its new production facilities, demonstrating the process of creating drones. Skyeton is known for its unmanned aerial systems (UAS), in particular the Raybird-3 system, which is one of its key developments. Raybird-3 is a modern unmanned system designed for reconnaissance missions and search and rescue operations. It has two modifications: civilian and military ACS-3. The military version is equipped with protection against electronic warfare and is capable of flying in automatic mode. The drone can stay in the air for over 24 hours, covering 2,000 km, and the operator can control it from a distance of up to 240 km. Background: Recently, the company announced a strategic partnership with Danish company Quadsat, which specialises in radio frequency research. Together, they will develop an aviation radio-electronic reconnaissance complex based on a special Danish-made QS RF Locator suspension module and the Ukrainian ACS-3 Raybird UAV. Support Ukrainska Pravda on Patreon!
Yahoo
a day ago
- Yahoo
New Potential Treatment Strategy for Brain Metastases and Leptomeningeal Disease: HER3-DXd Shows Promising Results in the Phase II TUXEDO-3 Study for Patients With Limited Therapeutic Options
The TUXEDO-3 trial is the first study to evaluate the intracranial and extracranial efficacy and safety of a novel anti-cancer drug in patients with breast and lung cancer and active brain metastases, and leptomeningeal disease from solid tumors. These results were presented as an oral presentation at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting, with select results simultaneously published in Nature Medicine. MEDSIR's DEMETHER clinical trial was mentioned during abstract discussion due to the relevance of its strategy. CHICAGO, June 04, 2025--(BUSINESS WIRE)--Leading international medical research company, MEDSIR announced today the positive results of the TUXEDO-3 trial at the American Society of Clinical Oncology (ASCO) Annual Meeting 2025. This phase II study funded by Daiichi Sankyo and Merck, known as MSD outside of the United States and Canada, evaluates the efficacy and safety of patritumab deruxtecan (HER3-DXd) in patients with active brain metastases and leptomeningeal disease, serious complications associated with advanced stages of the cancer. The study was carried out to evaluate HER3-DXd in patients with metastatic breast cancer (mBC) and advanced non-small cell lung cancer (aNSCLC) with active brain metastases, and patients with leptomeningeal disease from solid tumors. This is an antibody-drug conjugate to target HER3, a protein receptor found on the surface of cancer cells in brain metastases. HER3-DXd is an investigational agent consisting of a fully human anti-HER3 IgG1 monoclonal antibody attached to a number of topoisomerase I inhibitor payloads (an exatecan derivative, DXd) via tetrapeptide-based cleavable linkers. The DXd ADC Technology payload causes tumor DNA damage, killing cancer cells within and surrounding the tumor microenvironment The study showed promising results, which were presented today in an oral session. Results from the leptomeningeal cohort have been simultaneously published in the renowned journal Nature Medicine due to its potential benefit in patients with a high unmet medical need. In patients with breast cancer and brain metastases, intracranial responses were observed across all breast cancer subtypes, including luminal, HER2-positive, and triple-negative. A NEW HOPE FOR DIFFICULT-TO-TREAT METASTASES "This study represents a significant advancement in our understanding of how to treat brain metastases and leptomeningeal disease, and we are hopeful that our findings will pave the way for new, effective therapies for these patients," stated Dr. Matthias Preusser, MD, Medical Oncologist and Head of the Clinical Division of Oncology, Medical University of Vienna and Principal Investigator of TUXEDO-3. Dr. Rupert Bartsch, MD, PhD, Consultant Hematology and Medical Oncology, Medical University of Vienna, added: "Brain metastases and leptomeningeal disease represent severe complications in cancer, leading to increased morbidity and mortality, and HER3-DXd could be a promising therapeutic alternative for these patients." Read more about TUXEDO-3 here: SHOWCASING PROMISING COLLABORATIVE TRIALS AT ASCO MEDSIR's trial DEMETHER, an international, phase II trial exploring the maintenance of trastuzumab and pertuzumab following trastuzumab deruxtecan as induction treatment for HER2-positive recurrent metastatic breast cancer patients, was mentioned during today's Discussion of LBA1008. DEMETHER's strategy is to optimize the sequence to increase patients' progression free survival (PFS) while improving their quality of life. The relevance of this mention highlighted the ability of MEDSIR for anticipating patients' needs and designing strategical trials to keep on pushing the barriers of clinical research. MEDSIR active presence at the ASCO Annual Meeting 2025 reinforces its leadership in excellence-driven oncology research and highlights its focus on addressing unmet needs in cancer treatment, with the aim of not leaving any patient left behind. ABOUT MEDSIR For further information: View source version on Contacts Media Sergio Aguilar Eduardo Martín Espallargas
Business Wire
a day ago
- Business Wire
New Potential Treatment Strategy for Brain Metastases and Leptomeningeal Disease: HER3-DXd Shows Promising Results in the Phase II TUXEDO-3 Study for Patients With Limited Therapeutic Options
CHICAGO--(BUSINESS WIRE)--Leading international medical research company, MEDSIR announced today the positive results of the TUXEDO-3 trial at the American Society of Clinical Oncology (ASCO) Annual Meeting 2025. This phase II study funded by Daiichi Sankyo and Merck, known as MSD outside of the United States and Canada, evaluates the efficacy and safety of patritumab deruxtecan (HER3-DXd) in patients with active brain metastases and leptomeningeal disease, serious complications associated with advanced stages of the cancer. "This study represents a significant advancement in our understanding of how to treat brain metastases and leptomeningeal disease" - Dr. Matthias Preusser. Share The study was carried out to evaluate HER3-DXd in patients with metastatic breast cancer (mBC) and advanced non-small cell lung cancer (aNSCLC) with active brain metastases, and patients with leptomeningeal disease from solid tumors. This is an antibody-drug conjugate to target HER3, a protein receptor found on the surface of cancer cells in brain metastases. HER3-DXd is an investigational agent consisting of a fully human anti-HER3 IgG1 monoclonal antibody attached to a number of topoisomerase I inhibitor payloads (an exatecan derivative, DXd) via tetrapeptide-based cleavable linkers. The DXd ADC Technology payload causes tumor DNA damage, killing cancer cells within and surrounding the tumor microenvironment The study showed promising results, which were presented today in an oral session. Results from the leptomeningeal cohort have been simultaneously published in the renowned journal Nature Medicine due to its potential benefit in patients with a high unmet medical need. In patients with breast cancer and brain metastases, intracranial responses were observed across all breast cancer subtypes, including luminal, HER2-positive, and triple-negative. A NEW HOPE FOR DIFFICULT-TO-TREAT METASTASES 'This study represents a significant advancement in our understanding of how to treat brain metastases and leptomeningeal disease, and we are hopeful that our findings will pave the way for new, effective therapies for these patients,' stated Dr. Matthias Preusser, MD, Medical Oncologist and Head of the Clinical Division of Oncology, Medical University of Vienna and Principal Investigator of TUXEDO-3. Dr. Rupert Bartsch, MD, PhD, Consultant Hematology and Medical Oncology, Medical University of Vienna, added: 'Brain metastases and leptomeningeal disease represent severe complications in cancer, leading to increased morbidity and mortality, and HER3-DXd could be a promising therapeutic alternative for these patients.' MEDSIR's trial DEMETHER, an international, phase II trial exploring the maintenance of trastuzumab and pertuzumab following trastuzumab deruxtecan as induction treatment for HER2-positive recurrent metastatic breast cancer patients, was mentioned during today's Discussion of LBA1008. DEMETHER's strategy is to optimize the sequence to increase patients' progression free survival (PFS) while improving their quality of life. The relevance of this mention highlighted the ability of MEDSIR for anticipating patients' needs and designing strategical trials to keep on pushing the barriers of clinical research. MEDSIR active presence at the ASCO Annual Meeting 2025 reinforces its leadership in excellence-driven oncology research and highlights its focus on addressing unmet needs in cancer treatment, with the aim of not leaving any patient left behind.
